Your browser doesn't support javascript.
loading
JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.
Karjalainen, Riikka; Pemovska, Tea; Popa, Mihaela; Liu, Minxia; Javarappa, Komal K; Majumder, Muntasir M; Yadav, Bhagwan; Tamborero, David; Tang, Jing; Bychkov, Dmitrii; Kontro, Mika; Parsons, Alun; Suvela, Minna; Mayoral Safont, Mireia; Porkka, Kimmo; Aittokallio, Tero; Kallioniemi, Olli; McCormack, Emmet; Gjertsen, Bjørn T; Wennerberg, Krister; Knowles, Jonathan; Heckman, Caroline A.
Afiliação
  • Karjalainen R; Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
  • Pemovska T; Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
  • Popa M; Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Liu M; Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
  • Javarappa KK; Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
  • Majumder MM; Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
  • Yadav B; Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
  • Tamborero D; Research Unit on Biomedical Informatics, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
  • Tang J; Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
  • Bychkov D; Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
  • Kontro M; Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.
  • Parsons A; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; and.
  • Suvela M; Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
  • Mayoral Safont M; Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
  • Porkka K; Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Aittokallio T; Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.
  • Kallioniemi O; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; and.
  • McCormack E; Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
  • Gjertsen BT; Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
  • Wennerberg K; Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Knowles J; Hematology Section, Department of Internal Medicine, Haukeland University Hospital, Bergen, Norway.
  • Heckman CA; Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.
Blood ; 130(6): 789-802, 2017 08 10.
Article em En | MEDLINE | ID: mdl-28619982
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Sulfonamidas / Leucemia Mieloide Aguda / Compostos Bicíclicos Heterocíclicos com Pontes / Proteínas Proto-Oncogênicas c-bcl-2 / Janus Quinase 1 / Janus Quinase 2 / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Blood Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Sulfonamidas / Leucemia Mieloide Aguda / Compostos Bicíclicos Heterocíclicos com Pontes / Proteínas Proto-Oncogênicas c-bcl-2 / Janus Quinase 1 / Janus Quinase 2 / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Blood Ano de publicação: 2017 Tipo de documento: Article